Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants

Author(s)

Almeida, Volia De Carvalho ^[1] ; Mussi-Pinhata, Marisa Marcia ^[2] ; Sandoval De Souza, Cleonice Barbosa ^[2] ; Kubo, Christina Arslanian ^[3] ; Martinez, Edson Zangiacomi ^[4] ; Carneiro-Sampaio, Magda Maria ^[5] ; Duarte, Geraldo ^[6]

Affiliation

^[1] Univ Fed Sao Carlos, Biol & Hlth Sci Ctr, Dept Med, BR-13565905 Sao Carlos, SP - Brazil

^[2] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil

^[3] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508900 Sao Paulo - Brazil

^[4] Univ Sao Paulo, Dept Social Med, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil

^[5] Univ Sao Paulo, Dept Pediat, Fac Med, BR-05403900 Sao Paulo - Brazil

^[6] Univ Sao Paulo, Dept Gynecol & Obstet, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil

• Document type: Journal article
• Source: Vaccine; v. 27, n. 29, p. 3856-3861, JUN 12 2009.
• Web of Science Citations: 12

Abstract

Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 613, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants. (C) 2009 Elsevier Ltd. All rights reserved. (AU)